ARCA receives approval to begin with enrollment of first therapeutic trial with GeoVax vaccine GeoVax Labs, Inc. , a biotechnology company that creates, checks and develops innovative HIV/AIDS vaccines, announced today The AIDS Analysis Consortium of Atlanta has received acceptance to begin with enrollment of the initial therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc. Although the GeoVax vaccines are being studied for HIV prevention currently, this is the first research using the same products for treatment of persons who curently have HIV infections. ARCA may be the only site because of this trial.In April All were previous prize-winners at regional SABC competitions held across Canada. All 13 to 19 years old and enrolled in Grades 9 through 12, the college students were mentored by university professors and others who volunteer their expertise and several hours over several months each year to assist these young researchers. What sort of 16-year-older used a supercomputer to locate a promising brand-new treatment for cystic fibrosis Grade 11 student Marshall Zhang impressed many professionals when he utilized the Canadian SCINET supercomputing network to discover a new and possibly effective drug cocktail to treat cystic fibrosis.